Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
Immune checkpoint inhibitors (ICIs) represent a promising treatment for many kinds of cancers, including hepatocellular carcinoma (HCC). The rationale for using ICIs in HCC is based on the immunogenic background of hepatitis and cirrhosis and on the observation of high programmed death-ligand 1 (PD-...
Main Authors: | Piera Federico, Angelica Petrillo, Pasqualina Giordano, Davide Bosso, Antonietta Fabbrocini, Margaret Ottaviano, Mario Rosanova, Antonia Silvestri, Andrea Tufo, Antonio Cozzolino, Bruno Daniele |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/10/3025 |
Similar Items
-
Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them
by: Angelica Petrillo, et al.
Published: (2021-04-01) -
Resistance to Antiangiogenic Therapy in Hepatocellular Carcinoma: From Molecular Mechanisms to Clinical Impact
by: Piera Federico, et al.
Published: (2022-12-01) -
How to Treat Hepatocellular Carcinoma in Elderly Patients
by: Piera Federico, et al.
Published: (2021-03-01) -
Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
by: Tao Ouyang, et al.
Published: (2022-06-01) -
Research Progress on Immune Checkpoint Inhibitors in Treatment of Hepatocellular Carcinoma
by: CAO Jiali, et al.
Published: (2023-05-01)